147 related articles for article (PubMed ID: 32273248)
21. Spontaneous deep venous thrombosis: An unrecognized entity with sorafenib.
Madabhavi I; Patel A; Anand A; Choudhary M; Revannasiddaiah S
J Cancer Res Ther; 2015; 11(4):1029. PubMed ID: 26881607
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib-induced annular pustular psoriasis (Milian-Katchoura type).
Du-Thanh A; Girard C; Pageaux GP; Guillot B; Dereure O
Eur J Dermatol; 2013; 23(6):900-1. PubMed ID: 24184416
[No Abstract] [Full Text] [Related]
23. Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma.
Di Costanzo GG; Tortora R; De Luca M; Galeota Lanza A; Lampasi F; Tartaglione MT; Picciotto FP; Imparato M; Mattera S; Cordone G; Ascione A
Med Oncol; 2013 Mar; 30(1):446. PubMed ID: 23307255
[TBL] [Abstract][Full Text] [Related]
24. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
Zhu AX; Kudo M; Assenat E; Cattan S; Kang YK; Lim HY; Poon RT; Blanc JF; Vogel A; Chen CL; Dorval E; Peck-Radosavljevic M; Santoro A; Daniele B; Furuse J; Jappe A; Perraud K; Anak O; Sellami DB; Chen LT
JAMA; 2014 Jul; 312(1):57-67. PubMed ID: 25058218
[TBL] [Abstract][Full Text] [Related]
25. Liver abscess in advanced hepatocellular carcinoma after sorafenib treatment.
Shin SK; Jung YK; Yoon HH; Kwon OS; Kim YS; Choi DJ; Kim JH
Korean J Gastroenterol; 2014 Jan; 63(1):47-50. PubMed ID: 24463289
[TBL] [Abstract][Full Text] [Related]
26. Rhodotorula mucilaginosa skin infection in a patient treated with sorafenib.
Coppola R; Zanframundo S; Rinati MV; Carbotti M; Graziano A; Galati G; De Florio L; Panasiti V
J Eur Acad Dermatol Venereol; 2015 May; 29(5):1028-9. PubMed ID: 24628665
[No Abstract] [Full Text] [Related]
27. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Tajiri N; Satani M; Niizeki T; Aino H; Okamura S; Iwamoto H; Shimose S; Shirono T; Koga H; Torimura T;
Cancer Med; 2015 Dec; 4(12):1836-43. PubMed ID: 26471348
[TBL] [Abstract][Full Text] [Related]
28. Safety of sorafenib therapy in elderly adults with advanced hepatocellular carcinoma.
Francini E; Mazzaroppi S; Fiaschi AI; Petrioli R; Laera L; Roviello G; Pira T; Pellicelli AM; Bianco V
J Am Geriatr Soc; 2014 Nov; 62(11):2204-5. PubMed ID: 25413190
[No Abstract] [Full Text] [Related]
29. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
Inghilesi AL; Gallori D; Antonuzzo L; Forte P; Tomcikova D; Arena U; Colagrande S; Pradella S; Fani B; Gianni E; Boni L; Laffi G; Di Costanzo F; Marra F
World J Gastroenterol; 2014 Jan; 20(3):786-94. PubMed ID: 24574751
[TBL] [Abstract][Full Text] [Related]
30. Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma.
Ponziani FR; Bhoori S; Germini A; Bongini M; Flores M; Sposito C; Facciorusso A; Gasbarrini A; Mazzaferro V
Liver Int; 2016 Jul; 36(7):1033-42. PubMed ID: 26709844
[TBL] [Abstract][Full Text] [Related]
31. Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma.
Williet N; Clavel L; Bourmaud A; Verot C; Bouarioua N; Roblin X; Merle P; Phelip JM
Dig Liver Dis; 2017 Sep; 49(9):1043-1049. PubMed ID: 28712860
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON.
Kudo M; Ikeda M; Takayama T; Numata K; Izumi N; Furuse J; Okusaka T; Kadoya M; Yamashita S; Ito Y; Kokudo N
J Gastroenterol; 2016 Dec; 51(12):1150-1160. PubMed ID: 27106231
[TBL] [Abstract][Full Text] [Related]
34. Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy.
Akutsu N; Sasaki S; Takagi H; Motoya M; Shitani M; Igarashi M; Hirayama D; Wakasugi H; Yamamoto H; Kaneto H; Yonezawa K; Yawata A; Adachi T; Hamamoto Y; Shinomura Y
Int J Clin Oncol; 2015 Feb; 20(1):105-10. PubMed ID: 24744262
[TBL] [Abstract][Full Text] [Related]
35. Abdominal Distension in a Patient With Hepatocellular Carcinoma. Benign Pneumatosis Intestinalis and Pneumoperitoneum Associated With Sorafenib Therapy.
Huang YH; Siao FY; Yen HH
Gastroenterology; 2015 Aug; 149(2):e12-3. PubMed ID: 26123559
[No Abstract] [Full Text] [Related]
36. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study.
Naqi N; Ahmad S; Murad S; Khattak J
Hematol Oncol Stem Cell Ther; 2014 Mar; 7(1):27-31. PubMed ID: 24333135
[TBL] [Abstract][Full Text] [Related]
38. Sorafenib-induced Acute Pancreatitis: A Case Report and Review of the Literature.
Chou JW; Cheng KS; Huang CW
Intern Med; 2016; 55(6):623-7. PubMed ID: 26984079
[TBL] [Abstract][Full Text] [Related]
39. The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib.
Branco F; Alencar RS; Volt F; Sartori G; Dode A; Kikuchi L; Tani CM; Chagas AL; Pfiffer T; Hoff P; Carrilho FJ; Mattos AA
Ann Hepatol; 2017; 16(2):263-268. PubMed ID: 28233750
[TBL] [Abstract][Full Text] [Related]
40. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
